XTL Biopharmaceuticals Acquires 85% Stake in Beyond Air’s NeuroNOS Subsidiary

Reuters01-15

XTL Biopharmaceuticals Acquires 85% Stake in <a href="https://laohu8.com/S/XAIR">Beyond Air</a>’s NeuroNOS Subsidiary

XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002292), on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603460152?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603460152","market":"nz","top_or_hot":-1,"title":"XTL Biopharmaceuticals Acquires 85% Stake in Beyond Air’s NeuroNOS Subsidiary","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XTL Biopharmaceuticals Acquires 85% Stake in <a href=\"https://laohu8.com/S/XAIR\">Beyond Air</a>’s NeuroNOS Subsidiary\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002292), on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XTL Biopharmaceuticals Acquires 85% Stake in Beyond Air’s NeuroNOS Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXTL Biopharmaceuticals Acquires 85% Stake in Beyond Air’s NeuroNOS Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XTL Biopharmaceuticals Acquires 85% Stake in <a href=\"https://laohu8.com/S/XAIR\">Beyond Air</a>’s NeuroNOS Subsidiary\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002292), on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbVD2Sh:1","article_id":"2603460152","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603460152","pubTimestamp":1768476044,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder  and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","XAIR":"BEYOND AIR INC"},"translate_title":"XTL生物制药收购Beyond Air旗下NeuroNOS子公司85%股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAIR":0.9},"content_text":"XTL Biopharmaceuticals Acquires 85% Stake in Beyond Air’s NeuroNOS Subsidiary\n    \n\n        XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002292), on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603460152","isCrawlerRequest":true}